neuroQWERTY: a Transparent Patient-centered Outcome Method to Quantify Parkinsonian Motor Signs for Drug Trials (neuroQWERTY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02522065|
Recruitment Status : Completed
First Posted : August 13, 2015
Last Update Posted : April 4, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The motor impairment produced by Parkinson's disease (PD) is a significant and debilitating part of the condition. Current methods to evaluate this impairment rely on subjective examinations. The investigators seek to develop an objective assessment of motor deficits by monitoring the participants natural interactions with a keyboard (on a computer or smart device). This approach provides a window to how the brain behaves during typical daily use of these devices, i.e. writing a report, sending an email or any other task performed on a digital device and thus has the potential to be used easily and regularly. (Importantly, the data gathered are non-sensitive and based only on timing information).
PD participants will be recruited during outpatient visits to PD clinics throughout the Madrid metropolitan region. General entry criteria will be those patients who are scheduled to begin dopaminergic therapy, and own a home computer or laptop. The study will not impact on participants' standard clinical management other than by asking the participants to type for 15 minutes at each of the clinic visits, and installing the investigators proprietary software on their home computer. This software will collect keystroke data alone. (None of the actual information about what is being typed will be collected.) The keystroke data collected will be analyzed and compared with standard clinical metrics of therapeutic response, as well as the in-clinic typing data.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||Motor Response to Dopaminergic Therapy in a Population of de Novo Parkinson's Disease Cases Quantified Via Typing Analyses - -neuroQWERTY|
|Actual Study Start Date :||May 2015|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
Early Parkinson's disease cases
A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
- Percentage of participants with a motor response to medication > 4 UPDRS-III points detected by the developed algorithm (sensitivity to a motor change). [ Time Frame: 24-weeks ]A diagnostic table will be computed with all the study subjects. Those subjects with a clinical relevant response to medication (> 4 points in UPDRS - III) will be considered as true positives. Then, the accuracy of the typing test to detect them will be evaluated. For this purpose, the sensitivity, specificity, predictive values and ROC curve of a classification algorithm based on our nQ index will be computed. This will allow us assessing the validity of the test to identify a motor change. detected by the developed algorithm (sensitivity to a motor change).
- Agreement between nQ and UPDRS motor subscale [ Time Frame: 4,8,16,24-weeks ]Correlation (Spearman Rho) analyses between the indices and UPDRS
- Comparison between nQ and the different motor tests (Purdue Pegboard test score & Alternating Finger Tapping) [ Time Frame: 4,8,16,24-weeks ]Correlation (Spearman Rho) between the indices and motor test scores
- Effect of dopaminergic medication measured by nQ [ Time Frame: 4,8,16,24-weeks ]Correlation (Spearman Rho) between the indices and drug titration measured in L-Dopa equivalent milligrams
- Comparison between nQ and the CISI-PD, PDQ-39 and NMSS scales [ Time Frame: 4,8,16,24-weeks ]Correlation (Spearman Rho) between the indices and the CISI-PD, PDQ-39 and NMSS scales.
- Stability of the nQ index in a less controlled environment ("home-setting"). [ Time Frame: Week 1 ]Bland-Altman analyses to evaluate the stability of the indices in different days where the medication was not changed and therefore a change should not be expected
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Participants between 18 years and 70 years (older subjects will be deemed eligible on an individual basis after review by the study team).
- Parkinson's disease (PD) diagnosis according to the United Kingdom Brain Bank Criteria.
- PD patients without cognitive or psychiatric disturbances, as measured by the baseline assessment.
Prescription of symptomatic therapy with L-Dopa or dopamine agonists based on functional impairment attributed to PD. This will be based on the participant's physician criteria based on:
- Involvement of the dominant hand and/or upper limbs.
- Employed patients which the disease impairs their ability to work.
- Daily computer use > 30 minutes
- Mild cognitive impairment or dementia.
- Psychiatric symptoms
- Expected or current use of sedative medication (benzodiazepines, opiates, antihistaminergic drugs).
- Neuroleptic use.
- History of parkinsonism for the controls.
- Severe osteo-articular problems with upper limb functional limitation (amputations, severe osteo-arthritis).
- Alcohol risk use (>40 gr/day or 4 standard drinks for male / >24gr/day or 2 standard drinks for female).
- Narcolepsy or other sleep disorder producing hypersomnia (obstructive apnea, acute confusional states).
- Any other life- threatening condition (advanced cancer, severe hepatic or renal insufficiencies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02522065
|Fundacion Hospital Alcorcón|
|Alcorcón, Madrid, Spain, 28922|
|Hospital Universitario HM Puerta del Sur - Centro Integral de Neurociencias A.C.|
|Mostoles, Madrid, Spain, 28938|
|Hospital 12 de Octubre|
|Madrid, Please Select, Spain, 28041|
|Hospital de La Princesa|
|Madrid, Spain, 28006|
|Hospital Ramón y Cajal|
|Madrid, Spain, 28034|
|Hospital Clínico San Carlos|
|Madrid, Spain, 28040|
|Principal Investigator:||Jose Obeso, MD, PhD||Director at Centro Integral de Neurociencias A.C.|
|Responsible Party:||Fundación de investigación HM|
|Other Study ID Numbers:||
|First Posted:||August 13, 2015 Key Record Dates|
|Last Update Posted:||April 4, 2019|
|Last Verified:||April 2019|
Patient Outcome Assessment
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases